Τόμος 20 (2006) – Τεύχος 2 – Άρθρο 43 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 25 (2006) – Issue 2 – Article 43 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Title No association between the cholesteryl ester transfer protein gene-TaqlB polymorphism and coronary restenosis following percutaneous transluminal  coronary angioplasty
Authors S. Kaestner¹, N. Patsouras², C. Flordellis¹ and A. Manolis²

1. Department of Pharmacology, School of Medicine, University of Patras, Greece

2. Regional University General Hospital of Patras, Cardiology Division, Rio, Patras, Greece

Citation Kaestner, S., Patsouras, N., Flordellis, C., Manolis, A.: No association between the cholesteryl ester transfer protein gene-TaqlB polymorphism and coronary restenosis following percutaneous transluminal coronary angioplasty, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 178-180 (2006)
Publication Date Accepted for publication: 19-20 May 2006
Full Text Language English
Order – Buy  Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €) 

pharmakonpress[at]pharmakonpress[.]gr

Keywords Cholesteryl ester transfer protein, percutaneous transluminal coronary angioplasty, restenosis, TaqlB.
Other Terms review article
Summary The most widely studied variation at the cholesteryl ester transfer protein (CETP) gene locus is a silent base change called the TaqlB-polymorphism. TaqlB has been shown to affect levels/activity of CETP and plasma levels of high density lipoprotein cholesterol (HDL-C), and also to contribute to the risk of developing atherosclerosis and coronary heart disease (CHD). The primary objective of this study was to investigate the frequency of TaqlB and a possible association between this polymorphism and restenosis following percutaneous transluminal coronary angioplasty (PTCA) in Greek patients. As a secondary objective, the effect of TaqlB was assessed when accounting for various CHO risk factors, including a deletion in the α2B-adrenergic receptor gene. The frequency of TaqlB in this population was 54%. Either alone or in combination with CHD risk factors, TaqlB was not a significant predictor for assessing the risk of developing coronary restenosis following PTCA.
References 1. Kuivenhoven J.A., de Knijff P., Boer J.M.A., et al.: Arterioscler. Thromb. Vasc. Biol. 17: 560-568 (1997)

2. Ordovas J.M., Cupples A., Corella D., et al.: Thromb. Vasc. Biol. 20: 1323-1329 (2000)

3. Al-Daghri N.M., Al-Attas O., Patel A., et al.: Clin. Sci. 105: 467-472 (2003)

4. Kuivenhoven J.A., Jukema W., Zwinderman A.H., et al.: N. Engl. J. Med. 338: 86-93 (1998)

5.  Boer  J.M.A.,  Feskens  E.J.M.,  Kuivenhoven  J.A.,  et  al.: Atherosclerosis 155: 149-156 (2001)

6. Gudnason V., Kakko S., Nicaud V., et al.: Eur. J. Clin. Invest. 29: 116-128 (1999)

7. Hannuksela M.L., Liinamaa J.M., Kesaniemi Y.A., Savolainen M.J.: Atherosclerosis 110: 35-44 (1994)

8. Cohen J.C., Z.W., Grundy S.M., Stoesz M.R., Guerra R.: J Clin Invest 94: 2377-2384 (1994)

9. Corbex M., Poirier O., Fumeron F., et al.: Genet. Epidemiol. 19: 64-80 (2000)

10. Radeau T., Vohl M.C., Houde I., et al.: Nephron 84: 333- 341 (2000)

11. Vohl M.C., Lamarche B., Pascot A., et al.: Int. J. Obes. Relat. Metab. Disord. 23: 918-925 (1999)

12. Kastrati A., Dirschinger J., Schomig A.: Herz 25: 34-46 (2000)

13. Zee R.Y., Hoh J., Cheng S., et al.: Pharmacogenomics J. 2: 197-201 (2002)

14. Zee R.Y.L., Fernandez-Otiz A., Macaya C., Pintor E., Lindpaintner K., Fernandez-Cruz A.: J. Thromb. Haemost. 1: 1202-1207 (2003)

15. Dangas G., Kuepper F.: Circulation 105: 2586-2591 (2002)

16. Hamon M., Amant C, Bauters C, et al.: Am. J. Cardiol. 81: 79-81 (1998)

17. Inazu A, Koizumi J., Kajinami K., Kiyohar T., Chichibu K., Mabuchi H.: Atherosclerosis 145: 405-413 (1999)

18. Guerin M., Dolphin P.J., Talussot C., Gardette J., Berthezene F., Chapman M.J.: Arterioscler. Thromb. Vasc. Biol. 15: 1359-1368 (1995)

19. Freeman D.J., Griffin B.A., Holmes A.P., et al.: Arterioscler. Thromb. 14: 336-344 (1994)

20. Angerio A.D., Fink D.A.: Crit. Care Nurs. Q. 24: 62-68 (2001)

21. Bauters C., Hamon M., van Belle E., Dupuis B., Lablanche J.M., Bertrand M.E.: Arch. Mal. Coeur Vaiss. 86: 47-56 (1993)

22. Ribichini F., Ferrero V., Matullo G., et al.: Clin. Sci. 107: 381-389 (2004)

Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς – 
What is Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – 
Articles Published in Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006
Γλώσσα Πλήρους Κειμένου – Full Text Language Αγγλικά – English
Παραγγελία – Αγορά – Order – Buy Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)

pharmakonpress[at]pharmakonpress[.]gr

Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)

pharmakonpress[at]pharmakonpress[.]gr

 

 

 

 

Bookmark the permalink.

Comments are closed.